4553 TOWA PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4553

TSE Prime

TOWA PHARMACEUTICAL CO.,LTD.

2,625

JPY

-12

(-0.46%)

May 7, 3:30 pm JST

18.36

USD

May 7, 2:30 am EDT

Result

PTS

outside of trading hours

2,698

May 7, 9:27 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	154,900	19,923	18,677	13,958	283.6	44	May 14, 2021	J-GAAP
Mar, 2022	165,615	19,205	22,739	15,914	323.4	60	May 13, 2022	J-GAAP
Mar, 2023	208,859	5,514	5,141	2,201	44.7	60	May 15, 2023	J-GAAP
Mar, 2024	227,934	17,647	24,477	16,173	328.6	60	May 14, 2024	J-GAAP
Mar, 2025 Guidance	259,500	23,200	26,100	18,900	384.0	70	May 7, 2025	J-GAAP
YoY	+13.8%	+31.5%	+6.6%	+16.9%	+16.8%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 14, 2019	111,000	14,500	14,600	10,400	44*	J-GAAP
	Apr 30, 2020	110,000	16,000	20,500	14,000	44*	J-GAAP
Results	May 14, 2020	110,384	16,143	20,990	14,503	44*	J-GAAP
Mar, 2021	May 14, 2020	Available in future release
	Feb 12, 2021
Results	May 14, 2021
Mar, 2022	May 14, 2021
	Oct 26, 2021
	Feb 14, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Nov 14, 2022
	Feb 7, 2023
	Feb 13, 2023
	May 10, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Feb 13, 2024
Results	May 14, 2024
Mar, 2025	May 14, 2024	261,500	18,000	17,600	11,600	60	J-GAAP
	Aug 8, 2024	261,500	19,600	19,200	12,600	60	J-GAAP
	Nov 5, 2024	262,100	23,300	22,700	15,000	60	J-GAAP
	Feb 13, 2025	262,100	23,300	22,700	15,000	70	J-GAAP
	May 7, 2025	259,500	23,200	26,100	18,900	70	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	20,114	+2.7	Available in future release
Mar, 2001	18,406	-8.5
Mar, 2002	19,666	+6.8
Mar, 2003	21,046	+7.0
Mar, 2004	23,124	+9.9
Mar, 2005	24,763	+7.1
Mar, 2006	24,193	-2.3
Mar, 2007	29,235	+20.8
Mar, 2008	31,495	+7.7
Mar, 2009	35,966	+14.2
Mar, 2010	39,043	+8.6
Mar, 2011	46,145	+18.2
Mar, 2012	48,719	+5.6
Mar, 2013	55,241	+13.4
Mar, 2014	61,351	+11.1
Mar, 2015	71,470	+16.5
Mar, 2016	82,115	+14.9
Mar, 2017	84,949	+3.5
Mar, 2018	93,430	+10.0
Mar, 2019	105,104	+12.5
Mar, 2020	110,384	+5.0
Mar, 2021	154,900	+40.3
Mar, 2022	165,615	+6.9
Mar, 2023	208,859	+26.1
Mar, 2024	227,934	+9.1
Mar, 2025 Guidance	259,500	+13.8	23,200	+31.5	26,100	+6.6	384.0	+16.9

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	208,859	5,514	2.64	1.64	0.63	0.59	44.7
Mar, 2024	227,934	17,647	7.74	11.05	4.03	0.57	328.6
Mar, 2025 Guidance	259,500	23,200	8.94	11.18	4.12	0.57	384.0

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	227,934	19,923	24,477	16,173	328.6
Fiscal Year	Mar, 2024	Mar, 2021	Mar, 2024	Mar, 2024	Mar, 2024

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	83,361	8,893	9,731	6,672	135.6	33	May 13, 2022	J-GAAP
Oct - Mar, 2022	118,359	2,294	532	-491	-10.0	30	May 15, 2023	J-GAAP
Oct - Mar, 2023	120,538	10,644	14,244	9,220	187.3	30	May 14, 2024	J-GAAP
Oct - Mar, 2024 Guidance	136,096	12,687	15,762	12,345	250.8	40	May 7, 2025	J-GAAP
YoY	+12.9%	+19.2%	+10.7%	+33.9%	+33.9%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	19,205	-37,600	22,129	-59,729	46,540	32,830	9.89	J-GAAP
Mar, 2023	5,514	-27,740	2,544	-30,284	17,481	24,257	6.53	J-GAAP
Mar, 2024	17,647	-32,182	8,212	-40,394	35,407	29,650	6.88	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	140,405	5,352	4,639	1,984	40.3	90.2	Feb 13, 2023	J-GAAP
Apr - Dec, 2023	168,325	13,204	17,169	11,518	234.0	70.1	Feb 13, 2024	J-GAAP
Apr - Dec, 2024	193,737	18,611	21,756	14,624	297.1	95.8	Feb 13, 2025	J-GAAP
YoY	+15.1%	+40.9%	+26.7%	+27.0%	+26.9%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2023	68,454	162	502	217	4.4	0.2	May 15, 2023	J-GAAP
Apr - Jun, 2023	54,548	4,096	6,959	4,750	96.5	7.5	Aug 10, 2023	J-GAAP
Jul - Sep, 2023	52,848	2,907	3,274	2,203	44.8	5.5	Nov 13, 2023	J-GAAP
Oct - Dec, 2023	60,929	6,201	6,936	4,565	92.8	10.2	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	59,609	4,443	7,308	4,655	94.6	7.5	May 14, 2024	J-GAAP
Apr - Jun, 2024	62,566	5,672	8,593	5,495	111.6	9.1	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	60,838	4,841	1,745	1,060	21.5	8.0	Nov 12, 2024	J-GAAP
Oct - Dec, 2024	70,333	8,098	11,418	8,069	163.9	11.5	Feb 13, 2025	J-GAAP
YoY	+15.4%	+30.6%	+64.6%	+76.8%	+76.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2020	25,979	-3.1	Available in future release
Apr - Jun, 2020	37,900	+33.4
Jul - Sep, 2020	36,740	+36.4
Oct - Dec, 2020	40,611	+39.8
Jan - Mar, 2021	39,649	+52.6
Apr - Jun, 2021	42,927	+13.3
Jul - Sep, 2021	39,327	+7.0
Oct - Dec, 2021	43,359	+6.8
Jan - Mar, 2022	40,002	+0.9
Apr - Jun, 2022	45,372	+5.7
Jul - Sep, 2022	45,128	+14.8
Oct - Dec, 2022	49,905	+15.1
Jan - Mar, 2023	68,454	+71.1
Apr - Jun, 2023	54,548	+20.2
Jul - Sep, 2023	52,848	+17.1
Oct - Dec, 2023	60,929	+22.1
Jan - Mar, 2024	59,609	-12.9
Apr - Jun, 2024	62,566	+14.7
Jul - Sep, 2024	60,838	+15.1
Oct - Dec, 2024	70,333	+15.4	8,098	+30.6	11,418	+64.6	163.9	+76.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	70,333	8,098	11,418	8,069	163.9
Fiscal Year	Dec, 2024	Dec, 2024	Dec, 2024	Dec, 2024	Dec, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	2,685.18	39.8	332,097	132,169	122,131	1.06	May 13, 2022	J-GAAP
Mar, 2023	2,781.17	36.9	371,347	136,894	121,232	1.18	May 15, 2023	J-GAAP
Mar, 2024	3,167.27	36.2	430,653	155,893	134,452	1.30	May 14, 2024	J-GAAP
Apr - Dec, 2024	ー	36.8	459,004	169,023	146,140	1.32	Feb 13, 2025	J-GAAP

TOWA PHARMACEUTICAL CO.,LTD.(4553) Financial Results